Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
出版年份 2018 全文链接
标题
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
作者
关键词
-
出版物
BIODRUGS
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-30
DOI
10.1007/s40259-018-0303-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
- (2018) Mengjia Song et al. Chinese Journal of Cancer Research
- Inhibitors of the PD-1 Pathway in Tumor Therapy
- (2018) Martin W. LaFleur et al. JOURNAL OF IMMUNOLOGY
- Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
- (2018) C. Bryce Johnson et al. OncoImmunology
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
- (2017) Andrew W Hahn et al. Immunotherapy
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
- (2017) Nan Guo Ring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
- (2017) Sharareh Gholamin et al. Science Translational Medicine
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
- (2017) Lukasz Skalniak et al. Oncotarget
- Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer
- (2017) Adam S. Lazorchak et al. Cancer Immunology Research
- The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
- (2017) Christine Böger et al. OncoImmunology
- Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2016) Daphne Day et al. BIODRUGS
- Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy
- (2016) Pottayil Sasikumar et al. CANCER RESEARCH
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Pre-clinical efficacy in multiple syngeneic models with oral immune checkpoint antagonists targeting PD-L1 and TIM-3
- (2016) P. Sasikumar et al. EUROPEAN JOURNAL OF CANCER
- Immune checkpoint inhibitors side effects and management
- (2016) Hampig Raphael Kourie et al. Immunotherapy
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy
- (2015) Hao-Nan Chang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Paradigm shift in oncology: targeting the immune system rather than cancer cells
- (2015) T. Shekarian et al. MUTAGENESIS
- Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
- (2015) K. W. Yoon et al. SCIENCE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Tolerance and exhaustion: defining mechanisms of T cell dysfunction
- (2013) Andrea Schietinger et al. TRENDS IN IMMUNOLOGY
- In Vitro Measurement of Drug Efficiency Index to Aid Early Lead Optimization
- (2012) Klara Valko et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
- (2012) B. Edris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
- (2011) D. B. Flies et al. JOURNAL OF IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Physiochemical drug properties associated with in vivo toxicological outcomes
- (2008) Jason D. Hughes et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search